Clinical trial NCT04030000 - References

Uterine Carcinoma — Uterine Serous Carcinoma and Adjuvant Combined Intraperitoneal Chemotherapy and Radiation

Citation(s)

•   Aalders J, Abeler V, Kolstad P, Onsrud M
  Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol. 1980 Oct;56(4):419-27.
•   Abeler VM, Vergote IB, Kjorstad KE, Trope CG
  Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Cancer. 1996 Oct 15;78(8):1740-7. doi: 10.1002/(sici)1097-0142(19961015)78:83.0.co;2-y.
•   Ball HG, Blessing JA, Lentz SS, Mutch DG
  A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1996 Aug;62(2):278-81. doi: 10.1006/gyno.1996.0227.
•   Calais G, Vitu L, Descamps P, Body G, Reynaud-Bougnoux A, Lansac J, Bougnoux P, Le Floch O
  Preoperative or postoperative brachytherapy for patients with endometrial carcinoma stage I and II. Int J Radiat Oncol Biol Phys. 1990 Sep;19(3):523-7. doi: 10.101
•   Carey MS, O'Connell GJ, Johanson CR, Goodyear MD, Murphy KJ, Daya DM, Schepansky A, Peloquin A, Lumsden BJ
  Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarci
•   Elliott P, Green D, Coates A, Krieger M, Russell P, Coppleson M, Solomon J, Tattersall M
  The efficacy of postoperative vaginal irradiation in preventing vaginal recurrence in endometrial cancer. Int J Gynecol Cancer. 1994 Mar;4(2):84-93. doi: 10.1046/j.1525-1438.1994.04020084.x.
•   Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT
  Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Gr
•   Goff BA, Kato D, Schmidt RA, Ek M, Ferry JA, Muntz HG, Cain JM, Tamimi HK, Figge DC, Greer BE
  Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol. 1994 Sep;54(3):264-8. doi: 10.1006/gyno.1994.1208.
•   Greven KM, Curran WJ Jr, Whittington R, Fanning J, Randall ME, Wilder J, Peters AJ
  Analysis of failure patterns in stage III endometrial carcinoma and therapeutic implications. Int J Radiat Oncol Biol Phys. 1989 Jul;17(1):35-9. doi: 10.1016/0360-3016(89)
•   Greven KM, Lanciano RM, Corn B, Case D, Randall ME
  Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence. Cancer. 1993 Jun 1;71(11):3697-702. doi: 10.1002/1097-0142(19930601)71:113.0.co;2-u.
•   Greven KM, Randall M, Fanning J, Bahktar M, Duray P, Peters A, Curran WJ Jr
  Patterns of failure in patients with stage I, grade 3 carcinoma of the endometrium. Int J Radiat Oncol Biol Phys. 1990 Sep;19(3):529-34. doi: 10.1016/0360-3016(90)90477-2.
•   Grigsby PW, Perez CA, Camel HM, Kao MS, Galakatos AE
  Stage II carcinoma of the endometrium: results of therapy and prognostic factors. Int J Radiat Oncol Biol Phys. 1985 Nov;11(11):1915-23. doi: 10.1016/0360-3016(85)90272-x.
•   Gupta D, Gunter MJ, Yang K, Lee S, Zuckerwise L, Chen LM, Goldberg GL, Huang GS
  Performance of serum CA125 as a prognostic biomarker in patients with uterine papillary serous carcinoma. Int J Gynecol Cancer. 2011 Apr;21(3):529-34. doi: 10.1097/IGC.0b013e
•   Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R
  Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982 Mar;6(2):93-108. doi: 10.1097/00000478-198203000-00002.
•   Kato DT, Ferry JA, Goodman A, Sullinger J, Scully RE, Goff BA, Fuller AF Jr, Rice LW
  Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. Gynecol Oncol. 1995 Dec;59(3):384-9. doi: 10.1006/gyno.1995.9957.
•   Lanciano RM, Curran WJ Jr, Greven KM, Fanning J, Stafford P, Randall ME, Hanks GE
  Influence of grade, histologic subtype, and timing of radiotherapy on outcome among patients with stage II carcinoma of the endometrium. Gynecol Oncol. 1990 Dec;39(3):368-7
•   Mackillop WJ, Pringle JF
  Stage III endometrial carcinoma. A review of 90 cases. Cancer. 1985 Nov 15;56(10):2519-23. doi: 10.1002/1097-0142(19851115)56:103.0.co;2-m.
•   Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL, Yordan E, Brady MF
  Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993 Feb 15;71(4 Suppl):1702-9. doi: 10.1002/cncr.2820710440.
•   Martinez A, Podratz K, Schray M, Malkasian G
  Results of whole abdominopelvic irradiation with nodal boost for patients with endometrial cancer at high risk of failure in the peritoneal cavity. A prospective clinical trial at the Mayo Clinic. Hematol Onco
•   Mayr NA, Wen BC, Benda JA, Sorosky JI, Davis CS, Fuller RW, Hussey DH
  Postoperative radiation therapy in clinical stage I endometrial cancer: corpus, cervical, and lower uterine segment involvement--patterns of failure. Radiology. 1995 Aug;196(2):323-8.
•   Moore KN, Fader AN
  Uterine papillary serous carcinoma. Clin Obstet Gynecol. 2011 Jun;54(2):278-91. doi: 10.1097/GRF.0b013e318218c755.
•   Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, Graham JE
  Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol.
•   O'Hanlan KA, Levine PA, Harbatkin D, Feiner C, Goldberg GL, Jones JG, Rodriguez-Rodriguez L
  Virulence of papillary endometrial carcinoma. Gynecol Oncol. 1990 Apr;37(1):112-9. doi: 10.1016/0090-8258(90)90318-f.
•   Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, Thigpen JT, Benda JA; Gynecologic Oncology Group Study
  Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcin
•   Randall ME, Wilder J, Greven K, Raben M
  Role of intracavitary cuff boost after adjuvant external irradiation in early endometrial carcinoma. Int J Radiat Oncol Biol Phys. 1990 Jul;19(1):49-54. doi: 10.1016/0360-3016(90)90133-5.
•   Sherman ME, Devesa SS
  Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer. 2003 Jul 1;98(1):176-86. doi: 10.1002/cncr.11484.
•   Smith RS, Kapp DS, Chen Q, Teng NN
  Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy. Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):767-78. doi: 10.1016/s0360-3016(00)00724-0.
•   Sutton G, Axelrod JH, Bundy BN, Roy T, Homesley H, Lee RB, Gehrig PA, Zaino R
  Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006 Feb;100(2):349-54. doi: 10.1016/j.ygyno.2005.08.037. Epub 2005 Oct 5.
•   Sutton G, Axelrod JH, Bundy BN, Roy T, Homesley HD, Malfetano JH, Mychalczak BR, King ME
  Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol Oncol. 2005
•   Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA, Liao S
  Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2004 Oct 1;22(19):3902-8. doi: 10

A Pilot Phase II Trial of Intravenous Paclitaxel and Intraperitoneal Carboplatin/Taxol Followed by Radiation in Patients With Advanced Stage Uterine Serous Carcinoma

Details for clinical trial NCT04030000